PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1475-1487

  Ma, Wenxue ^a   Chen, Mingshui ^a   Kaushal, Sharmeela ^a,b   McElroy, Michele ^a,b   Zhang, Yu ^c   Ozkan, Cengiz ^c   Bouvet, Michael ^a,b   Kruse, Carol ^d   Grotjahn, Douglas ^e   Ichim, Thomas ^f   Minev, Boris ^a,g,h  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SAN DIEGO STATE UNIVERSITY   (United States)

^f Medistem Inc   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h GENELUX CORPORATION   (United States)

Author keywords

Dendritic cells; Nanotechnology; Peptide delivery; Vaccination

Indexed keywords

FREUND ADJUVANT; MELAN A; NANOPARTICLE; OVALBUMIN; POLY(DEXTRO LEVEO LACTIDE CO GLYCOLIDE)NANOPARTICLE; POLYGLACTIN; PROSTATE ANTIGEN; TRANSMEMBRANE EPITHELIAL PROSTATE ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER INHIBITION; CELL TRANSFER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOTOXICITY; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PROTEIN TRANSPORT; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CHEMISTRY; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; NANOMEDICINE; NANOTECHNOLOGY; PATHOLOGY; PROSTATE TUMOR; SCANNING ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, INTRAPERITONEAL; LACTIC ACID; MALE; MART-1 ANTIGEN; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; POLYGLYCOLIC ACID; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84866747868     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29506     Document Type: Article

References (57)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411(6835):380-384.
2. Sloan JM, Kershaw MH, Touloukian CE, et al. MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Ther. 2002;9(11):946-950.
3. Steinman RM. Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. Nat Med. 2007;13(10): 1155-1159.
4. Epaulard O, Toussaint B, Quenee L, et al. Anti-tumor immunotherapy via antigen delivery from a live attenuated genetically engineered Pseudomonas aeruginosa type III secretion system-based vector. Mol Ther. 2006;14(5):656-661.
5. Murthy N, Campbell J, Fausto N, Hoffman AS, Stayton PS. Bioinspired pH-responsive polymers for the intracellular delivery of biomolecular drugs. Bioconjug Chem. 2003;14(2):412-419.
6. Spies T, Cerundolo V, Colonna M, Cresswell P, Townsend A, DeMars R. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature. 1992;355(6361):644-646.
7. Lehner PJ, Cresswell P. Processing and delivery of peptides presented by MHC class I molecules. Curr Opin Immunol. 1996;8(1):59-67.
8. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909-915.
9. Noguchi M, Mine T, Komatsu N, et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther. 2011;10(12):1266-1279.
10. Brunsvig PF, Kyte JA, Kersten C, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 2011;17(21):6847-6857.
11. Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine. 2007;25(19):3731-3741.
12. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2(8):469-478.
13. Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer. 2004;112(2):335-340.
14. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release. 2005;102(2):373-381.
15. Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C. PLGA nanoparticle-peptide conjugate effectively targets intercellular celladhesion molecule-1. Bioconjug Chem. 2008;19(1):145-152.
16. Campolongo MJ, Luo D. Drug delivery: old polymer learns new tracts. Nat Mater. 2009;8(6):447-448.
17. Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol Pharm. 2004;1(3):211-219.
18. Prabha S, Zhou WZ, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm. 2002;244(1-2):105-115.
19. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16(10): 1217-1226.
20. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat. 2005;4(4):363-374.
21. Ma W, Smith T, Bogin V, et al. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. J Transl Med. 2011;9:34.
22. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000;97(9):4796-4801.
23. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23(11):1407-1413.
24. Mailliard RB, Egawa S, Cai Q, et al. Complementary dendritic cellactivating function of CD8ffand CD4aaT cells: helper role of CD8T T cells in the development of T helper type 1 responses. J Exp Med. 2002;195(4):473-483.
25. Craiu A, Akopian T, Goldberg A, Rock KL. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci U S A. 1997;94(20):10850-10855.
26. Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. 2007;67(3):1344-1351.
27. Ma W, Yu H, Wang Q, Jin H, Solheim J, Labhasetwar V. A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol. 2004;24(3):294-301.
28. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine sixtransmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res. 2001;61(15): 5857-5860.
29. Ito F, Fujimori H, Makino K. Factors affecting the loading efficiency of water-soluble drugs in PLGA microspheres. Colloids Surf B Biointerfaces. 2008;61(1):25-29.
30. Rosenberg SA, Kawakami Y, Robbins PF, Wang R. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res. 1996;70:145-177.
31. Rew SB, Peggs K, Sanjuan I, et al. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24. Clin Cancer Res. 2005;11(9):3377-3384.
32. Xiang SD, Scalzo-Inguanti K, Minigo G, Park A, Hardy CL, Plebanski M. Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines. 2008;7(7):1103-1119.
33. Mandelboim O, Vadai E, Fridkin M, et al. Regression of established murine carcinoma metastases following vaccination with tumourassociated antigen peptides. Nat Med. 1995;1(11):1179-1183.
34. Mesa C, Fernandez LE. Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol. 2004;82(6):644-650.
35. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol. 1999;17(11):1075-1081.
36. Fifis T, Gamvrellis A, Crimeen-Irwin B, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004;173(5):3148-3154.
37. Yadav KS, Chuttani K, Mishra AK, Sawant KK. Effect of Size on the Biodistribution and Blood Clearance of Etoposide-Loaded PLGA Nanoparticles. PDA J Pharm Sci Technol. 2011;65(2):131-139.
38. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta. 2009;1788(10): 2259-2266.
39. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-515.
40. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63(3):170-183.
41. Tsai YM, Chien CF, Lin LC, Tsai TH. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm. 2011;416(1):331-338.
42. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008;105(7):2586-2591.
43. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105(45):17356-17361.
44. Benny O, Menon LG, Ariel G, et al. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth. Clin Cancer Res. 2009;15(4):1222-1231.
45. Kaiser-Schulz G, Heit A, Quintanilla-Martinez L, et al. Polylactidecoglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses. J Immunol. 2007;179(5):2797-2807.
46. Wang X, Wenk E, Hu X, et al. Silk coatings on PLGA and alginate microspheres for protein delivery. Biomaterials. 2007;28(28): 4161-4169.
47. Tse MT, Blatchford C, Oya Alpar H. Evaluation of different buffers on plasmid DNA encapsulation into PLGA microparticles. Int J Pharm. 2009;370(1-2):33-40.
48. Pearton M, Allender C, Brain K, et al. Gene delivery to the epidermal cells of human skin explants using microfabricated microneedles and hydrogel formulations. Pharm Res. 2008;25(2):407-416.
49. Jessel N, Oulad-Abdelghani M, Meyer F, et al. Multiple and timescheduled in situ DNA delivery mediated by beta-cyclodextrin embedded in a polyelectrolyte multilayer. Proc Natl Acad Sci U S A. 2006;103(23):8618-8621.
50. Choleris E, Little SR, Mong JA, Puram SV, Langer R, Pfaff DW. Microparticle-based delivery of oxytocin receptor antisense DNA in the medial amygdala blocks social recognition in female mice. Proc Natl Acad Sci U S A. 2007;104(11):4670-4675.
51. Sirsi SR, Schray RC, Wheatley MA, Lutz GJ. Formulation of polylactide-co-glycolic acid nanospheres for encapsulation and sustained release of poly(ethylene imine)-poly(ethylene glycol) copolymers complexed to oligonucleotides. J Nanobiotechnology. 2009;7(1):1.
52. Goforth R, Salem AK, Zhu X, et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother. 2009;58(4):517-530.
53. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 2004;22(19):2406-2412.
54. Lutsiak ME, Kwon GS, Samuel J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol. 2006;58(6):739-747.
55. Hamdy S, Molavi O, Ma Z, et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8iiT cell-mediated anti-tumor immunity. Vaccine. 2008;26(39):5046-5057.
56. Newman KD, Samuel J, Kwon G. Ovalbumin peptide encapsulated in poly(d, l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J Control Release. 1998;54(1):49-59.
57. Diwan M, Elamanchili P, Lane H, Gainer A, Samuel J. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target. 2003;11(8-10):495-507.